Octreotide Acetate



Octreotide Acetate





(ok tree’ oh tide)

Sandostatin, Sandostatin LAR Depot

PREGNANCY CATEGORY B


Drug Classes

Antidiarrheal

Hormone


Therapeutic Actions

Mimics the natural hormone somatostatin; suppresses secretion of serotonin, gastrin, vasoactive intestinal peptide, insulin, glucagon, secretin, motilin, and pancreatic polypeptide; also suppresses growth hormone and decreases splanchnic blood flow.


Indications



  • Symptomatic treatment of patients with metastatic carcinoid tumors to suppress or inhibit the associated severe diarrhea and flushing episodes


  • Treatment of the profuse watery diarrhea associated with vasoactive intestinal polypeptide tumors (VIPomas)


  • Reduction of growth hormone blood levels in patients with acromegaly not responsive to other treatment


  • Unlabeled uses: GI fistula, variceal bleeding, diarrheal states, pancreatic fistulas, IBS, dumping syndrome



Available Forms

Injection—0.05, 0.1, 0.2, 0.5, 1 mg/mL; depot injection—10, 20, 30 mg/5 mL


Dosages

Adults

Subcutaneous injection is the route of choice. Initial dose is 50 mcg subcutaneously two to three times daily; the number of injections is increased based on response, usually bid–tid. IV bolus injections have been used in emergency situations—not recommended. Depot injection: Do not administer IV or subcutaneously; inject intragluteally at 4-wk intervals. Patients should be stabilized on subcutaneous octreotide for at least 2 wk before switching to long-acting depot.

Jul 21, 2016 | Posted by in NURSING | Comments Off on Octreotide Acetate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access